who else can we blame?

Everyone is quick to point out how poorly ACL has performed since the approval of Fonda. However unless you've been hiding under a rock (Or only follow NEU)- then you would have realized that a majority of this sector has been hit hard. Sure we have done worst than most, but now have more upside than most aswell.....

Here are some popular biotech’s from my watchlist.

The difference below is from the high to low in the last 6 odd months.

ACR down 30%
OBJ down 36%
BTA- down-37%
ADO- down 43%
CDY- down 49%
ISN- down 52%
BLT- down 52%
ANP- down 53%
EMS- down 58%
GTG- down 58%
PRR- down 57%
ACL- down 65%
AHZ- down 66%
PXS- down 79%


Guess it must be because of how the director and board have handled things as well? ;)